SCHEMBL6947800

SCHEMBL6947800

Cn1cc(C(CC(=O)N2CCC(O)(Cc3ccccc3)CC2)c2cnc(=O)[nH]c2)c(=O)nc1SCc1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PLA2G7 Q13093 18/20 0.39
USP19 O94966 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6949746 0.83 PLA2G7 (0.47) PLA2G7
SCHEMBL6947739 0.81 PLA2G7 (0.52) PLA2G7
SCHEMBL6947323 0.79 PLA2G7 (0.43) PLA2G7
SCHEMBL7221064 0.75 PLA2G7 (0.46) PLA2G7
SCHEMBL7008378 0.75 PLA2G7 (0.47) PLA2G7
SCHEMBL6951481 0.75 PLA2G7 (0.44) PLA2G7
SCHEMBL6951245 0.75 PLA2G7 (0.50) PLA2G7
SCHEMBL6954832 0.75 PLA2G7 (0.58) PLA2G7
SCHEMBL6949723 0.75 PLA2G7 (0.51) PLA2G7
SCHEMBL6947762 0.75 PLA2G7 (0.51) PLA2G7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1105377-B1 PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 2003-10-08 EP claimed
US-6559155-B1 Phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 inhibitors SMITHKLINE BEECHAM P.L.C. (GB) 2003-05-06 US claimed
EP-1105377-A1 PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 2001-06-13 EP claimed
WO-2000010980-A1 PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 2000-03-02 WO claimed
US-6559155-B1 Phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 inhibitors SMITHKLINE BEECHAM P.L.C. (GB) 2003-05-06 US disclosed